<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38526146</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-5598</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of hypertension</Title><ISOAbbreviation>J Hypertens</ISOAbbreviation></Journal><ArticleTitle>Complete remission with histamine blocker in a patient with intractable hyperadrenergic postural orthostatic tachycardia syndrome secondary to long coronavirus disease syndrome.</ArticleTitle><Pagination><StartPage>928</StartPage><EndPage>932</EndPage><MedlinePgn>928-932</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/HJH.0000000000003669</ELocationID><Abstract><AbstractText>The COVID-19 pandemic caused by the novel severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), has emerged as a global public health concern and its sequels have barely started to outcrop. A good percentage of patients who suffered from COVID-19 are prone to develop long-COVID or post-COVID condition (PCC), a multisystemic, heterogeneous, chronic disorder. Patients with PCC may experience diverse manifestations, of which cardiovascular and neurological symptoms are among the most frequently reported. Indeed, dysautonomia presented as orthostatic intolerance has gained room following recent reports linking postural orthostatic tachycardia syndrome (POTS) with PCC. Disturbances in heart rate (HR) and blood pressure (BP) during postural changes are the cornerstones of orthostatic intolerance seen in patients suffering from PCC. A subtype of POTS, hyperadrenergic POTS, has been widely studied because of its association with mast cell activation syndrome (MCAS). Although a causative relationship between PCC, hyperadrenergic POTS, and MCAS remains unrevealed, these syndromes can overlap. We want to propose here a correlation produced by a close-loop mechanism with positive feedback established after SARS-CoV-2 infection in a previously healthy young patient.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Alvarez</LastName><ForeName>Felipe</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratory of Autonomic Nervous System, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esta&#xf1;ol</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory of Autonomic Nervous System, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Hermosillo</LastName><ForeName>Jes&#xfa;s Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Dysautonomia Clinic, Instituto Nacional de Cardiologia Ignacio Chavez.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-P&#xe9;rez</LastName><ForeName>Francisco Javier</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of Endocrinology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamez-Torres</LastName><ForeName>Karla Maria</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Infectology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pe&#xf1;a</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Autonomic Nervous System, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cant&#xfa;</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiquete</LastName><ForeName>Erwin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sifuentes-Osornio</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alba-Lorenzo</LastName><ForeName>Maria Del Carmen</ForeName><Initials>MDC</Initials><AffiliationInfo><Affiliation>Dysautonomia Clinic, Instituto Nacional de Cardiologia Ignacio Chavez.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Celestino-Montelongo</LastName><ForeName>Dulce Andrea</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Dysautonomia Clinic, Instituto Nacional de Cardiologia Ignacio Chavez.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salazar-Calder&#xf3;n</LastName><ForeName>Guadalupe E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aceves Buendia</LastName><ForeName>Jose de Jesus</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Mexico City, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Hypertens</MedlineTA><NlmUniqueID>8306882</NlmUniqueID><ISSNLinking>0263-6352</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>820484N8I3</RegistryNumber><NameOfSubstance UI="D006632">Histamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054972" MajorTopicYN="Y">Postural Orthostatic Tachycardia Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054971" MajorTopicYN="Y">Orthostatic Intolerance</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006632" MajorTopicYN="N">Histamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>25</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>25</Day><Hour>9</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38526146</ArticleId><ArticleId IdType="pmc">PMC10990027</ArticleId><ArticleId IdType="doi">10.1097/HJH.0000000000003669</ArticleId><ArticleId IdType="pii">00004872-990000000-00432</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz J. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022; 22:e102&#x2013;e107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et al. . Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med 2023; 183:566&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. . Postacute COVID-19 syndrome. Nat Med 2021; 27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Author correction: long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21:408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10408714</ArticleId><ArticleId IdType="pubmed">37069455</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xe5;hlberg M, Reistam U, Fedorowski A, Villacorta H, Horiuchi Y, Bax J, et al. . Post-COVID-19 tachycardia syndrome: a distinct phenotype of post-acute COVID-19 syndrome. Am J Med 2021; 134:1451&#x2013;1456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8356730</ArticleId><ArticleId IdType="pubmed">34390682</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernino S, Bourne KM, Stiles LE, Grubb BP, Fedorowski A, Stewart JM, et al. . Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1. Auton Neurosci 2021; 235:102828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8455420</ArticleId><ArticleId IdType="pubmed">34144933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanjwal K, Saeed B, Karabin B, Kanjwal Y, Grubb BP. Clinical presentation and management of patients with hyperadrenergic postural orthostatic tachycardia syndrome. A single center experience. Cardiol J 2011; 18:527&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">21947988</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibao C, Arzubiaga C, Roberts LJ, 2nd, Raj S, Black B, Harris P, et al. . Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension 2005; 45:385&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">15710782</ArticleId></ArticleIdList></Reference><Reference><Citation>Arun S, Storan A, Myers B. Mast cell activation syndrome and the link with long COVID. Br J Hosp Med (Lond) 2022; 83:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">35938771</ArticleId></ArticleIdList></Reference><Reference><Citation>Valent P, Akin C, Nedoszytko B, Bonadonna P, Hartmann K, Niedoszytko M, et al. . Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine. Int J Mol Sci 2020; 21:9030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7731385</ArticleId><ArticleId IdType="pubmed">33261124</ArticleId></ArticleIdList></Reference><Reference><Citation>Valent P, Hartmann K, Bonadonna P, Niedoszytko M, Triggiani M, Arock M, Brockow K. Mast cell activation syndromes: Collegium Internationale Allergologicum Update 2022. Int Arch Allergy Immunol 2022; 183:693&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9393812</ArticleId><ArticleId IdType="pubmed">35605594</ArticleId></ArticleIdList></Reference><Reference><Citation>Batiha GE, Al-Kuraishy HM, Al-Gareeb AI, Welson NN. Pathophysiology of post-COVID syndromes: a new perspective. Virol J 2022; 19:158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9548310</ArticleId><ArticleId IdType="pubmed">36210445</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis 2020; 100:327&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Kempuraj D. Role of SARS-CoV-2 spike-protein-induced activation of microglia and mast cells in the pathogenesis of neuro-COVID. Cells 2023; 12:688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10001285</ArticleId><ArticleId IdType="pubmed">36899824</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L, Laksono BM, de Vrij FMS, Kushner SA, Harschnitz O, van Riel D. The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2. Trends Neurosci 2022; 45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8890977</ArticleId><ArticleId IdType="pubmed">35279295</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukiw WJ, Pogue A, Hill JM. SARS-CoV-2 infectivity and neurological targets in the brain. Cell Mol Neurobiol 2022; 42:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445393</ArticleId><ArticleId IdType="pubmed">32840758</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke J, L&#xfc;tgehetmann M, Hagel C, Sperhake JP, Schr&#xf6;der AS, Edler C, et al. . Neuropathology of patients with COVID-19 in Germany: a postmortem case series. Lancet Neurol 2020; 19:919&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7535629</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond) 2021; 53:737&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian H, Gupta K, Ali H. Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases. J Allergy Clin Immunol 2016; 138:700&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014572</ArticleId><ArticleId IdType="pubmed">27448446</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallick D, Goyal L, Chourasia P, Zapata MR, Yashi K, Surani S. COVID-19 induced postural orthostatic tachycardia syndrome (POTS): a review. Cureus 2023; 15:e36955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10065129</ArticleId><ArticleId IdType="pubmed">37009342</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>